A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
Status:
Recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
This research study is studying a novel type of CLL vaccine as a possible treatment for
chronic lymphocytic leukemia (CLL)
The names of the study interventions involved in this study are:
- Personalized NeoAntigen Vaccine
- Poly-ICLC
- Cyclophosphamide
- Pembrolizumab
Phase:
Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
BioNTech SE Merck Sharp & Dohme Corp. Neon Therapeutics, Inc. Oncovir, Inc.